NICE updates COVID-19 rapid guideline on delivery of systemic anticancer treatments (NG161), following review of evidence of their effects on risk of severe illness or death [NG161], NICE (updated 12th February 2021)

New recommendations include the addition of Covid-19 vaccination status as a factor to be considered when assessing risk (recommendation 3.3) and the importance of reaching a shared decision on risks and benefits of treatment changes/breaks (recommendation 4.5).
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news